the severity of most aefis was mild-to-moderate, and the severity and number of aefis were less in the older age group. in the first quarter of the vaccination, hcws were administered the bnt162b2 mrna vaccine (pfizer/biontech) or chadox1 ncov-19 vaccine (astrazeneca). the hcws were asked to fill a preliminary form that captured the previous history of vaccination, covid-19, and allergies. a total of 1,503 hcws were vaccinated, and the data of 994 hcws was reported in the mvaers (994/1,503, 66.1%).
most of the local aefis were grade 1 and 2 in severity; however, the frequency of local aefis of grade 3 or above was higher than that of systemic aefis. the severity of most aefis was mild-to-moderate, and the severity and number of aefis were less in the older age group. to manage with aefis, we developed and used mvaers during the first quarter of vaccination. in conclusion, fatigue and mild-to-moderate pain or tenderness at the injection site were frequently reported after the chadox1 ncov-19 vaccination. aefis were graded on a scale of 1 to 4 based on the guidelines of the korean ministry of food and drug safety and u.s. food and drug administration (supplementary table 2).
an event that may not be immediately life-threatening but requires intervention to prevent 1 of the outcomes listed above and may also be considered as serious. clinical information on the aefi is reviewed and categorized into 1 of 5 categories. doses administered used for reporting rate calculations have been adjusted to account for the delay between vaccination and reporting. reports of 11-year-olds who received the pfizer-biontech comirnaty covid-19 vaccine dose for individuals 12 years of age and older before the pediatric dose was authorized are included in the 5 to 11 age group.
note: 73 of the 46,149 covid-19 adverse event reports (0.16%), involved people who received an influenza vaccine and a covid-19 vaccine on the same day. reports of 11-year-olds who received the pfizer-biontech comirnaty covid-19 vaccine dose for individuals 12 years of age and older before the pediatric dose was authorized are included in the 5 to 11 age group. 3the 5 to 11 year age group also includes reports of individuals born in 2017 who had not yet turned 5 years old at the time of vaccination. these reports do not imply a causal relationship between the vaccine and the adverse event.
adverse event following immunization is any untoward medical occurrence which follows immunization and which does not necessarily have a causal relationship rare instances of adverse events following covid-19 vaccinations have been reported to the vaccine adverse event reporting system. have you had a reaction following a vaccination? contact your healthcare provider. report an adverse event using the vaers online form or the downloadable pdf., .
the vaccine adverse event reporting system (vaers) is a passive reporting system, meaning it relies on individuals to send in reports of their experiences. the most commonly reported aefis were tenderness at the injection site (94.5%), fatigue (92.9%), pain at the injection site (88.0%), and malaise however, several adverse events associated with covid-19 vaccines have been reported, including anaphylaxis, transverse myelitis, and deep vein, .
When you try to get related information on adverse events following vaccination, you may look for related areas. .